全反式维甲酸联合三氧化二砷诱导治疗急性早幼粒细胞白血病期间的白细胞增多可预测分化综合征及治疗相关并发症
该研究在三个意大利高专业化中心纳入65例低中危急性早幼粒细胞白血病患者,均接受全反式维甲酸联合三氧化二砷诱导治疗。39/65(60%)出现白细胞增多,均经羟基脲成功处理;多因素分析证实诊断时纤维蛋白原水平较低是白细胞增多的最强预测因素(OR 0.36,0.15-0.72,p=0.009)。分化综合征及其他治疗相关并发症几乎仅见于发生白细胞增多的患者。
要点
- 低中危急性早幼粒细胞白血病患者接受全反式维甲酸联合三氧化二砷诱导治疗时,白细胞增多发生率为60%(39/65)。
- 诊断时纤维蛋白原水平较低是多因素分析中白细胞增多的最强预测因素(OR 0.36,0.15-0.72,p=0.009)。
- 分化综合征及其他治疗相关并发症几乎仅见于发生白细胞增多的患者。
核心结论
- 低中危急性早幼粒细胞白血病患者接受全反式维甲酸联合三氧化二砷诱导治疗期间,诊断时纤维蛋白原水平较低、血小板计数较低及骨髓原始细胞浸润程度较高者应密切监测白细胞增多。
- 分化综合征及其他治疗相关并发症似乎几乎仅见于发生白细胞增多的患者,此类患者应接受分化综合征预防及更密集的监测和支持治疗以预防治疗并发症。
研究设计与样本
- 研究为队列研究,纳入三个意大利高专业化中心共65例接受全反式维甲酸联合三氧化二砷治疗的低中危急性早幼粒细胞白血病患者。
主要发现
- 65例中39例(60%)发生白细胞增多,白细胞计数峰值最常出现在诊断后第二周。
- 单因素分析中白细胞增多的预测因素包括:较低血小板计数(OR 0.98,0.97-1.00,p=0.018)、较低纤维蛋白原水平(OR 0.36,0.17-0.66,p=0.003)、较高骨髓原始细胞浸润(OR 1.03,1.01-1.07,p=0.021)及流式检测CD117表达(OR 1.04,1.01-1.08,p=0.012)。
- 多因素分析证实诊断时纤维蛋白原水平较低是白细胞增多的最强预测因素(OR 0.36,0.15-0.72,p=0.009)。
- 分化综合征仅见于发生白细胞增多的患者,与白细胞计数升高严格相关(16/39 vs. 0/26,p<0.001)。
- 其他治疗相关并发症(包括QTc间期延长、心脏事件、肝脏及血液学毒性)在发生白细胞增多的患者中显著更常见(22/39 vs. 3/26,p<0.001)。
临床怎么用
- 所有发生白细胞增多的病例均经羟基脲成功处理。
- 作者认为,诊断时纤维蛋白原水平较低、血小板计数较低及骨髓原始细胞浸润程度较高的患者应密切监测诱导期间白细胞增多的发生。
- 作者认为,发生白细胞增多的患者应接受分化综合征预防及更密集的监测和支持治疗以预防治疗并发症。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
All-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) represent the standard of care for low-intermediate risk acute promyelocytic leukaemia (APL). Leucocytosis during induction with ATRA-ATO represents a common complication with an incidence of up to 60%. To identify predictive factors for this complication, we studied a cohort of 65 low-intermediate risk APL patients treated with ATRA-ATO in three highly specialized Italian centres. Overall, 39/65 (60%) patients developed leucocytosis, with a peak in leucocyte count being most frequent in the second week from diagnosis. All cases were successfully managed with hydroxyurea. Predictive factors for leucocytosis in univariate analysis were lower platelet counts (odds ratio [OR] 0.98, 0.97-1.00, p = 0.018), lower fibrinogen levels (OR 0.36, 0.17-0.66, p = 0.003), higher bone marrow blast infiltration (OR 1.03, 1.01-1.07, p = 0.021) and CD117 expression by flow (OR 1.04, 1.01-1.08, p = 0.012). Multivariate analysis confirmed lower levels of fibrinogen at diagnosis as the strongest predictive factor for the development of leucocytosis (OR 0.36, 0.15-0.72, p = 0.009). Differentiation syndrome (DS) occurred only in patients developing leucocytosis showing a strict correlation with rising leucocytes counts (16/39 vs. 0/26, p < 0.001). In addition, other treatment-related complications including QTc prolongation, cardiac events, liver, and haematological toxicities were significantly more frequent in patients experiencing leucocytosis (22/39 vs. 3/26, p < 0.001). In conclusion, APL patients undergoing ATRA-ATO therapy with lower fibrinogen levels and platelet counts at diagnosis and with a massive bone marrow blast infiltrate should be carefully monitored for the development of leucocytosis during induction. DS and other treatment-related complications seem to occur almost exclusively in patients developing leucocytosis, who should necessarily receive DS prophylaxis and more intensive monitoring and supportive therapy to prevent treatment complications.
引用
- Cicconi L, Bisegna M, Gurnari C, et al. Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications. Br J Haematol. 2024. PMID: 39275865. doi:10.1111/bjh.19759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。